The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Regulatory News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10.10
Bid: 9.70
Ask: 10.50
Change: 0.00 (0.00%)
Spread: 0.80 (8.247%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 10.10
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

26 Jul 2011 13:01

For filings with the FSA include the annex For filings with issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are Scancell Holdings plc attached:ii 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments An event changing the breakdown of voting rights Other (please specify): 3. Full name of person(s) subject to the Calculus Capital Limitednotification obligation:iii 4. Full name of shareholder(s) HSBC Global Custody (UK) Limited (if different from 3.):iv 5. Date of the transaction and date on which the threshold is crossed or 26 July 2011reached: v 6. Date on which issuer notified: 26 July 2011 7. Threshold(s) that is/are crossed or 10,11,12,13%reached: vi, vii 8. Notified details: A: Voting rights attached to shares viii, ix Class/type Situation previous Resulting situation after the triggering of to the triggering transaction shares transaction Number Number Number Number of voting % of voting rightsif possible of of of shares rights x using Shares Voting the ISIN Rights Direct Direct xi Indirect Direct Indirect CODE xii Ordinary Shares ISIN: 15,277,780 15,277,780 25,277,780 25,277,780 13.02 % GB00B39J5N63 B: Qualifying Financial Instruments Resulting situation after the triggering transaction Type of Expiration Exercise/ Number of voting % of voting financial date xiii Conversion Period xiv rights that may be rights instrument acquired if the instrument is exercised/ converted. C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi Resulting situation after the triggering transaction Type of Exercise price Expiration Exercise/ Number of voting % of voting financial date xvii Conversion rights instrument rights xix, xx instrument period refers to xviii Nominal Delta Total (A+B+C) Number of voting rights Percentage of voting rights 25,277,780 13.02 %

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

N/A Proxy Voting: 10. Name of the proxy holder: N/A 11. Number of voting rights proxy holder will cease N/Ato hold: 12. Date on which proxy holder will cease to hold N/Avoting rights: 13. Additional information: N/A 14. Contact name: Calculus Capital Limited 15. Contact telephone number: 0207 493 4940

Note: Annex should only be submitted to the FSA not the issuer Annex: Notification of major interests in sharesxxii A: Identity of the persons or legal entity subject to the notification obligation Full name (including legal form of legal entities) Contact address (registered office for legal entities) Phone number & email Other useful information (at least legal representative for legal persons)

B: Identity of the notifier, if applicable Full name Contact address Phone number & email Other useful information (e.g. functional relationship with the person or legal entity subject to the notification obligation) C: Additional information

For notes on how to complete form TR-1 please see the FSA website.

XLON
Date   Source Headline
12th Aug 20147:00 amRNSSynergy of SCIB1 with checkpoint inhibitors
19th Jun 20147:00 amRNSDirector/PDMR Shareholding
6th Jun 20147:00 amRNSDNA ImmunoBody Patent Granted in United States
2nd Jun 20147:00 amRNSUpdate on Phase 1/2 trial of SCIB1 in melanoma
15th May 20147:30 amRNSPresents latest SCIB1 data at ASCO
9th May 20148:30 amRNSDirectorate Change
1st May 20147:00 amRNSDr Sally Adams to Join as Development Director
4th Apr 20147:00 amRNSScancell to present SCIB1 at AACR
21st Mar 20147:00 amRNS8mg Higher Dose SCIB1 Study On Track
18th Feb 20147:00 amRNSPublication of Moditope Patent
11th Feb 20147:00 amRNSSCIB1 Granted FDA Orphan Drug Status
10th Feb 20144:43 pmRNSHolding(s) in Company
6th Jan 20147:00 amRNSNottingham Technology Grant
16th Dec 20137:00 amRNSNottingham Trent University Cancer Protein Study
12th Dec 20137:00 amRNSDNA ImmunoBody Patent Granted in Japan
11th Dec 20137:00 amRNSDirector/PDMR Shareholding
9th Dec 20137:00 amRNSHalf Yearly Report
9th Dec 20137:00 amRNSNew data for SCIB1 in metastatic melanoma
18th Nov 20137:00 amRNSRe Agreement with Ichor
1st Nov 20134:56 pmRNSAGM Statement
22nd Oct 20138:00 amRNSDirector/PDMR Shareholding
14th Oct 201310:10 amRNSHolding(s) in Company
8th Oct 20132:54 pmRNSNotice of AGM
1st Oct 20137:00 amRNSInvestor Update
24th Sep 20137:00 amRNSInvestor Update Agenda
10th Sep 20133:06 pmRNSInvestor Day
3rd Sep 20137:00 amRNSDNA ImmunoBody Patent Granted in first market
20th Aug 20137:00 amRNSInclusion on Frankfurt Stock Exchange
12th Aug 20135:16 pmRNSDirector/PDMR Shareholding
8th Aug 20133:15 pmRNSHolding(s) in Company
5th Aug 20132:17 pmRNSHolding(s) in Company
1st Aug 201311:39 amRNSResult of General Meeting
26th Jul 20137:00 amRNSResult of Open Offer
23rd Jul 20137:00 amRNSDirector/PDMR Shareholding
19th Jul 20134:40 pmRNSSecond Price Monitoring Extn
19th Jul 20134:35 pmRNSPrice Monitoring Extension
12th Jul 20137:00 amRNSResearch Update
10th Jul 201310:55 amRNSAnnual Financial Report
9th Jul 20137:00 amRNSProposed Firm Placing and Open Offer
9th Jul 20137:00 amRNSFinal Results
9th Apr 20137:00 amRNSAppointment of Non-Executive Director
14th Mar 20137:00 amRNSRe: The Journal of Clinical Investigation Paper
27th Feb 20132:00 pmRNSDirectorate Change
6th Feb 20137:00 amRNSImmunoBody patent approved for grant in Japan
31st Jan 20137:00 amRNSHalf Yearly Report
29th Jan 20137:00 amRNSUpdate on patient recruitment in clinical trial
12th Dec 20127:00 amRNSDirectorate Change
12th Dec 20127:00 amRNSSCIB1 Trial-Higher Dose Allowed in Phase 1/2 Trial
6th Dec 20127:00 amRNSUpdate on SCIB1 Phase 1/2 clinical trial
3rd Dec 20129:30 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.